Back to Search Start Over

Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)

Authors :
Anne Godier
Pierre Fontana
Serge Motte
Annick Steib
Fanny Bonhomme
Sylvie Schlumberger
Thomas Lecompte
Nadia Rosencher
Sophie Susen
André Vincentelli
Yves Gruel
Pierre Albaladejo
Jean-Philippe Collet
P. Albaladejo
S. Belisle
N. Blais
F. Bonhomme
A. Borel-Derlon
J.Y. Borg
J.-L. Bosson
A. Cohen
J.-P. Collet
E. de Maistre
D. Faraoni
P. Fontana
D. Garrigue Huet
A. Godier
Y. Gruel
J. Guay
J.F. Hardy
Y. Huet
B. Ickx
S. Laporte
D. Lasne
J.H. Levy
J. Llau
G. Le Gal
T. Lecompte
S. Lessire
D. Longrois
S. Madi-Jebara
E. Marret
J.L. Mas
M. Mazighi
P. Mismetti
P.E. Morange
S. Motte
F. Mullier
N. Nathan
P. Nguyen
Y. Ozier
G. Pernod
N. Rosencher
S. Roullet
P.M. Roy
C.M. Samama
S. Schlumberger
J.F. Schved
P. Sié
A. Steib
S. Susen
E. van Belle
P. van Der Linden
A. Vincentelli
P. Zufferey
UCL - (MGD) Service d'anesthésiologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Laboratoire de biologie clinique
Source :
Anaesthesia, critical care & pain medicine, Vol. 37, no. 4, p. 379-389 (2018), Anaesthesia Critical Care and Pain Medicine, 37 (4
Publication Year :
2018

Abstract

The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy in patients undergoing elective invasive procedures. The proposals were discussed and validated by a vote; all proposals but one could be assigned with a high strength. The management of antiplatelet therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can be divided into high, moderate and low categories depending on the possibility of performing the procedure in patients receiving antiplatelet agents (none, monotherapy and dual antiplatelet therapy respectively). If discontinuation of antiplatelet therapy is indicated before the procedure, a last intake of aspirin, clopidogrel, ticagrelor and prasugrel 3, 5, 5 and 7 days before surgery respectively is proposed. The thrombotic risk associated with discontinuation should be assessed according to each specific indication of antiplatelet therapy and is higher for patients receiving dual therapy for coronary artery disease (with further refinements based on a few well-accepted items) than for those receiving monotherapy for cardiovascular prevention, for secondary stroke prevention or for lower extremity arterial disease. These proposals also address the issue of the potential role of platelet functional tests and consider management of antiplatelet therapy for regional anaesthesia, including central neuraxial anaesthesia and peripheral nerve blocks, and for coronary artery surgery.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Details

Language :
English
Database :
OpenAIRE
Journal :
Anaesthesia, critical care & pain medicine, Vol. 37, no. 4, p. 379-389 (2018), Anaesthesia Critical Care and Pain Medicine, 37 (4
Accession number :
edsair.doi.dedup.....b9cbc7949c6fa4ae422ff0ac9c709601